Company / Cash & Equivalents
Eledon Pharmaceuticals, Inc. Cash & Equivalents History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$24.0M
FY2016
5-year range
$11.7M / $31.8M
FY2014-FY2016
Trend
-24.3%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $12M to $24M over the past 2 years.
Based on SEC 10-K filings.
$24M in FY2016.
Improved from $12M to $24M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, cash & equivalents decreased 24.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | $24.0M | -24.3% |
| FY2015 | $31.8M | +171.6% |
| FY2014 | $11.7M | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026